You are here

Merck

Could a New COVID Pill Crush Vaccine Sales?

Motley Fool

Tue, 10/5/21 - 10:45 am

Ridgeback Biotherapeutics

Is the cancer immunotherapy market up for disruption as AstraZeneca, Regeneron-Sanofi, cheaper Chinese offerings line up?

Fierce Pharma

Sun, 10/3/21 - 08:27 pm

cancer immunotherapy

Trouble builds for Merck's $11.5B Acceleron buy as activist investor behind Gilead's Immunomedics deal says too early, too cheap

Fierce Pharma

Fri, 10/1/21 - 10:55 am

Merck & Co justifies paying up for Acceleron

EP Vantage

Fri, 10/1/21 - 10:46 am

Merck says research shows its COVID-19 pill works against variants

Reuters

Thu, 09/30/21 - 11:13 pm

Delta COVID-19 variant

Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug

BioSpace

Thu, 09/30/21 - 12:01 am

Oncology the focus for big pharma catalysts

EP Vantage

Tue, 09/28/21 - 11:19 am

Gilead Sciences

Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report

Endpoints

Tue, 09/28/21 - 12:15 am

Merck touts a confirmatory Keytruda win for liver cancer as 'dangling' accelerated approval saga marches on

Endpoints

Mon, 09/27/21 - 10:48 am

clinical trials

Insurers sue Merck for 'monopolistic scheme' to delay generics of blockbuster cholesterol drug

BioPharma Dive

Sat, 09/25/21 - 02:14 pm

Merck will pay royalties on next-gen pneumococcal shot to settle Pfizer patent fight

Fierce Pharma

Fri, 09/24/21 - 11:58 am

pneumococcal disease

PROpel study backs Lynparza combo in first-line prostate cancer

Pharmaforum

Fri, 09/24/21 - 11:06 am

clinical trials

prostate cancer

Merck women's health spinoff Organon debuts first awareness campaign, taking on unplanned pregnancy

Fierce Pharma

Tue, 09/21/21 - 10:53 pm

ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda

Pharmaforum

Mon, 09/20/21 - 11:07 am

non-small cell lung cancer

Could Pfizer and Merck Be Big Winners With COVID Pills?

Motley Fool

Mon, 09/20/21 - 12:02 am

drug development

Merck fleshes out Keytruda win in first-line cervical cancer, adding more firepower to its early cancer push

Endpoints

Sat, 09/18/21 - 08:29 pm

cervical cancer

World Lung 2021 – front-line competition lines up behind Keytruda

EP Vantage

Tue, 09/14/21 - 10:43 am

CStone Pharmaceuticals

Shanghai Junshi Biosciences

Bellus says its Merck cough rival passed a PhIIb test after earlier flop, but investors can't make up their minds

Endpoints

Mon, 09/13/21 - 10:40 am

clinical trials

Merck Investors Have Reason to Cheer This Label Expansion

Motley Fool

Thu, 09/9/21 - 10:54 am

triple negative breast cancer

Illumina and Merck Partner to ID Cancer Mutations

Medical Devices and Diagnostics Industry

Wed, 09/8/21 - 11:20 pm

homologous recombination deficiency

Pages